CLLS Quote, Financials, Valuation and Earnings

Akari Therapeutics PLC has a net margin of -170.14% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -49.15% beat Akari Therapeutics PLC's return on equity of --.

Cellectis SA has a consensus price target of $5.75, signalling upside risk potential of 320.69%. On the other hand Akari Therapeutics PLC has an analysts' consensus of $7.00 which suggests that it could grow by 497.88%. Given that Akari Therapeutics PLC has higher upside potential than Cellectis SA, analysts believe Akari Therapeutics PLC is more attractive than Cellectis SA.

Cellectis SA has a beta of 2.924, which suggesting that the stock is 192.353% more volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.247, suggesting its less volatile than the S&P 500 by 75.292%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $10.7M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Cellectis SA's net income of -$18.1M is lower than Akari Therapeutics PLC's net income of -$3.7M. Notably, Cellectis SA's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 2.80x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -170.14% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -49.15% beat DBV Technologies SA's return on equity of --.

Cellectis SA has a consensus price target of $5.75, signalling upside risk potential of 320.69%. On the other hand DBV Technologies SA has an analysts' consensus of $14.76 which suggests that it could grow by 52.3%. Given that Cellectis SA has higher upside potential than DBV Technologies SA, analysts believe Cellectis SA is more attractive than DBV Technologies SA.

Cellectis SA has a beta of 2.924, which suggesting that the stock is 192.353% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.624, suggesting its less volatile than the S&P 500 by 162.448%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $10.7M, which are larger than DBV Technologies SA quarterly revenues of --. Cellectis SA's net income of -$18.1M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Cellectis SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 2.80x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -170.14% compared to Cellectis SA's net margin of -52.18%. Cellectis SA's return on equity of -49.15% beat Edap TMS SA's return on equity of -49.1%.

Cellectis SA has a consensus price target of $5.75, signalling upside risk potential of 320.69%. On the other hand Edap TMS SA has an analysts' consensus of $5.75 which suggests that it could grow by 224.86%. Given that Cellectis SA has higher upside potential than Edap TMS SA, analysts believe Cellectis SA is more attractive than Edap TMS SA.

Cellectis SA has a beta of 2.924, which suggesting that the stock is 192.353% more volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.015, suggesting its less volatile than the S&P 500 by 98.469%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $10.7M, which are smaller than Edap TMS SA quarterly revenues of $14.3M. Cellectis SA's net income of -$18.1M is lower than Edap TMS SA's net income of -$7.4M. Notably, Cellectis SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 2.80x versus 0.98x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -170.14% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -49.15% beat Genfit SA's return on equity of --.

Cellectis SA has a consensus price target of $5.75, signalling upside risk potential of 320.69%. On the other hand Genfit SA has an analysts' consensus of $8.70 which suggests that it could grow by 115.94%. Given that Cellectis SA has higher upside potential than Genfit SA, analysts believe Cellectis SA is more attractive than Genfit SA.

Cellectis SA has a beta of 2.924, which suggesting that the stock is 192.353% more volatile than S&P 500. In comparison Genfit SA has a beta of 1.148, suggesting its more volatile than the S&P 500 by 14.837%.

Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Cellectis SA quarterly revenues are $10.7M, which are larger than Genfit SA quarterly revenues of --. Cellectis SA's net income of -$18.1M is higher than Genfit SA's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 2.80x versus 2.79x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.